Chemical subgroup
B02BX – Andere systemische Hämostatika
13Decisions
15Patient groups
Added benefit by patient group
- Considerable1
- Non-quantifiable1
- Not proven13
Decisions, newest first
- 2026-03-19AlhemoConcizumabNot proven
- 2026-03-19AlhemoConcizumabNot proven
- 2025-10-16AlhemoConcizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-10-16AlhemoConcizumabNot proven
- 2025-07-17HympavziMarstacimabNot proven
- 2025-07-17HympavziMarstacimabNot proven
- 2023-08-17HemlibraEmicizumabNot proven
- 2022-05-19Mulpleo (previously Lusutrombopag Shionogi)LusutrombopagNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2020-12-17TavlesseFostamatinibNot proven
- 2019-09-05HemlibraEmicizumabNot proven
- 2018-09-20HemlibraEmicizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29